Patient Characteristics and Disease Modifying Therapy use in Patients with Late Onset Multiple Sclerosis: A 30-year Retrospective Review

被引：0
|
作者：
Ahmad, S. [1 ]
Perez-Giraldo, G. [2 ]
Caldito, N. Gonzalez [2 ]
Grebenciucova, E. [2 ]
Balabanov, R. [2 ]
Cohen, B. [2 ]
Graham, E. L. [2 ]
机构：
[1] Univ Nevada, Kirk Kerkorian Sch Med, Las Vegas, NV USA
[2] Northwestern Univ, Dept Neurol Div Multiple Sclerosis & neuroimmunol, Chicago, IL USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P472
引用
收藏
页码：236 / 236
页数：1
相关论文
共 50 条
  • [21] Inappropriate use of disease-modifying therapy in severely disabled patients with progressive multiple sclerosis
    Lonergan, R.
    Kinsella, K.
    Duggan, M.
    Jordan, S.
    Hutchinson, M.
    Tubridy, N.
    JOURNAL OF NEUROLOGY, 2009, 256 : S160 - S160
  • [22] INAPPROPRIATE USE OF DISEASE-MODIFYING THERAPY IN SEVERELY DISABLED PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS
    Lonergan, R.
    Kinsella, K.
    Jordan, S.
    Duggan, M.
    Hutchinson, M.
    Tubridy, N.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (11):
  • [23] Infections in patients with multiple sclerosis: Implications for disease-modifying therapy
    Celius, E. G.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 : 34 - 36
  • [24] Impact of disease modifying therapy on fatigue among multiple sclerosis patients
    Elkhooly, Mahmoud
    Raghib, Muhammad
    Lazar, Emily
    Lazar, Adam
    Liaquat, Zaima
    Martinez, Carla
    Rube, Jacob
    Bernitsas, Evanthia
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1028 - 1028
  • [25] FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
    Meletiche, D. M.
    Kozma, C.
    Dickson, M.
    VALUE IN HEALTH, 2009, 12 (03) : A193 - A193
  • [26] Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis
    MacDonald, Sarah C.
    McElrath, Thomas F.
    Hernandez-Diaz, Sonia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (04) : 556 - 560
  • [27] Late-onset multiple sclerosis in Iran: A report on demographic and disease characteristics
    Ghadiri, Fereshteh
    Sahraian, Mohammad Ali
    Razazian, Nazanin
    Ashtari, Fereshteh
    Poursadeghfard, Maryam
    Nabavi, Seyed Massood
    Navardi, Samira
    Baghbanian, Seyed Mohammad
    Shaygannejad, Vahid
    Harirchian, Mohammad Hossein
    Beladimoghadam, Nahid
    Majdinasab, Nastaran
    Hosseini, Samaneh
    Azimi, Amirreza
    Kamali, Hoda
    Sharifipour, Ehsan
    Mir, Nahid Hosseini Nejad
    Bayati, Asghar
    Nahayati, Mohammad Ali
    Heidari, Hora
    Mozhdehipanah, Hossein
    Langroodi, Hamidreza Ghalyanchi
    Jalali, Nazanin
    Ayoubi, Saeideh
    Asadollahzadeh, Elnaz
    Ebadi, Zahra
    Eskandarieh, Sharareh
    Moghadasi, Abdorreza Naser
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 70
  • [28] Examining the Effects of Comorbidities on Disease-Modifying Therapy Use in Multiple Sclerosis
    Zhang, Tingting
    Tremlett, Helen
    Leung, Stella
    Zhu, Feng
    Kingwell, Elaine
    Fisk, John
    Bhan, Virender
    Campbell, Trudy
    Yu, Nancy
    Marrie, Ruth-Ann
    NEUROLOGY, 2016, 86
  • [29] Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis
    Zhang, Tingting
    Tremlett, Helen
    Leung, Stella
    Zhu, Feng
    Kingwell, Elaine
    Fisk, John D.
    Bhan, Virender
    Campbell, Trudy L.
    Stadnyk, Karen
    Yu, B. Nancy
    Marrie, Ruth Ann
    NEUROLOGY, 2016, 86 (14) : 1287 - 1295
  • [30] Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
    Molazadeh, Negar
    Sahraian, Mohammad Ali
    Ghajarzadeh, Mahsa
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2023, 14 (01) : 89 - 93
12345